Claims for Patent: 10,047,343
✉ Email this page to a colleague
Summary for Patent: 10,047,343
Title: | Methods for producing cartilage and bone |
Abstract: | The present disclosure provides methods of producing cartilage in vitro. The present disclosure provides treatment methods, involving introducing in vitro-produced cartilage into a treatment site in vivo. The present disclosure provides methods of enhancing bone formation, the method involving introducing in vitro-produced hypertrophic cartilage into a treatment site in vivo. |
Inventor(s): | Kuo; Alfred (San Francisco, CA) |
Assignee: | |
Application Number: | 14/599,324 |
Patent Claims: | 1. A method of generating hypertrophic cartilage in vitro, the method comprising: a) culturing in a first liquid medium in vitro a starting population of chondrocytes,
wherein the first liquid medium is serum free and comprises a transforming growth factor-.beta., (TGF.beta.) isoform wherein said culturing provides for an at least 50-fold increase in the number of chondrocytes over the number of chondrocytes in the
starting population, thereby generating an expanded chondrocyte population; and b) culturing the expanded chondrocyte in vitro in a second liquid medium, wherein the second liquid medium is serum free and comprises a bone morphogenetic protein (BMP)
isoform and optionally a transforming growth factor-.beta. (TGF.beta.) isoform, wherein aggrecan and type II collagen expression is greater when the chondrocytes are expanded and cultured in the first and second liquid medium instead of serum containing
medium; and said culturing in the second liquid medium results in production of hypertrophic cartilage.
2. The method of claim 1, wherein the TGF.beta. isoform comprises an amino acid sequence having at least 95% amino acid sequence identity to a TGF-.beta. amino acid sequence set forth in any of SEQ ID NOs: 1-4 and 9. 3. The method of claim 1, wherein the TGF.beta. isoform is TGF-.beta.1, TGF-.beta.2, or TGF-.beta.3. 4. The method of claim 1, wherein the BMP isoform comprises an amino acid sequence having at least 95% amino acid sequence identity to a BMP amino acid sequence set forth in any of SEQ ID NOs: 5 and 6. 5. The method of claim 1, wherein the BMP isoform is a BMP-4 isoform. 6. The method of claim 1, wherein the starting population of chondrocytes is substantially pure. 7. The method of claim 1, further comprising preparing a matrix composition comprising the cells. 8. A method of generating permanent cartilage in vitro, the method comprising a) culturing in a first liquid medium in vitro a starting population of chondrocytes, wherein the first liquid medium is serum free and comprises a transforming growth factor-.beta., (TGF.beta.) isoform, wherein said culturing provides for an at least 50-fold increase in the number of chondrocytes over the number of chondrocytes in the starting population, thereby generating an expanded chondrocyte population; and b) culturing the expanded chondrocyte in vitro in a second liquid medium, wherein the second liquid medium is serum free and comprises a bone morphogenetic protein (BMP) isoform and optionally a transforming growth factor-.beta. (TGF.beta.) isoform, wherein the second liquid medium further includes a parathyroid hormone-related (PTHrP) isoform, wherein aggrecan and type II collagen expression is greater when the chondrocytes are expanded and cultured in the first and second liquid medium instead of serum containing medium; and said culturing in the second liquid medium results in production of permanent cartilage. 9. The method of claim 8, wherein the TGF.beta. isoform comprises an amino acid sequence having at least 95% amino acid sequence identity to a TGF-0 amino acid sequence set forth in any of SEQ ID NOs: 1-4 and 9. 10. The method of claim 8, wherein the TGF.beta. isoform is TGF-01, TGF-02, or TGF-03. 11. The method of claim 8, wherein the BMP isoform comprises an amino acid sequence having at least 95% amino acid sequence identity to a BMP amino acid sequence set forth in any of SEQ ID NOs: 5 and 6. 12. The method of claim 8, wherein the BMP isoform is a BMP-4 isoform. 13. The method of claim 8, wherein the PTHrP isoform comprises an amino acid sequence having at least 95% amino acid sequence identity to a PTHrP amino acid sequence set forth in any of SEQ ID NOs: 8 and 10. 14. The method of claim 8, wherein the starting population of chondrocytes is substantially pure. |
Details for Patent 10,047,343
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2032-07-20 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.